1. In Vivo
  2. >>Leadership

Texas Justice and the Industry's Image

With its $253 million judgment against Merck & Co. Inc. (reduced to $26.1 million under Texas law), the jury "sent a message" about what it perceived as the pharmaceutical industry's culture of greed. Ironically Merck's liability gives it a rare opportunity to right the ship. But will industry's tarnished image impede the approval and use of Merck's most important upcoming product, the HPV vaccine Gardasil?

It would be tough to claim that the Texas jury's decision in favor of the woman who claimed her husband was killed by rofecoxib (Vioxx) reflected medical truth. But the fact that Robert Ernst probably didn't die of a heart attack—much less one that was caused by Vioxx—was beside the point. With its $253 million judgment against Merck & Co. Inc. (reduced to $26.1 million under Texas law), the jury "sent a message" about what it perceived as the pharmaceutical industry's culture of greed.

The industry is unlikely to hear that message: its executives simply don't believe it. Too often we've heard them dismiss...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Leadership

Surgical Robotics CEOs Talk Metrics For Success, Valuations And Competition

 
• By Marion Webb

Leaders of robotic systems companies Distalmotion, Neocis and Noah Medical discussed success metrics, competition and funding. Institutional investors are focusing on utilization, procedure rates and a clear path to profitability as the IPO window reopens, BTIG analyst Ryan Zimmerman said.

‘A Small Medtech Industry Ecosystem With An Outsized Global Influence’

 
• By Ashley Yeo

Entrepreneurialism is in the blood of Israel’s medtech innovators, but in a changing medtech world, the local ecosystem must address funding gaps and manufacturing and infrastructure needs. So says Ruti Alon, experienced Israeli medtech leader, investor and co-chair of the Biomed Israel conference.

Podcast: Poolbeg CEO On The Biotech’s Big Bet On Small Molecules

 
• By Jo Shorthouse

In the latest episode of the In Vivo Podcast, Jeremy Skillington, CEO of Poolbeg Pharma, discussed the company’s ambitious pipeline and strategic direction.

Infographic: How Big Pharma Is Scaling Beyond Pilot AI Projects

 
• By David Wild

Pharma leaders are shifting from AI pilots to enterprise-scale deployment, favoring external partnerships for efficiency gains while maintaining tight control over sensitive clinical data.

More from In Vivo

‘A Small Medtech Industry Ecosystem With An Outsized Global Influence’

 
• By Ashley Yeo

Entrepreneurialism is in the blood of Israel’s medtech innovators, but in a changing medtech world, the local ecosystem must address funding gaps and manufacturing and infrastructure needs. So says Ruti Alon, experienced Israeli medtech leader, investor and co-chair of the Biomed Israel conference.

Dealmaking Quarterly Statistics, Q2 2025

 
• By Maureen Riordan and Deanna Kamienski

During Q2, biopharma merger and acquisition deal value reached $24.6bn and drew in $60.7bn in potential deal value from alliances. Device company M&A values reached $223m, while in vitro diagnostics and research tools players’ M&A activity totaled $802m.

PBMs Tighten The Reins: Value Becomes The New Access Gatekeeper

 
• By Andrew Cox

Facing rising costs and tighter regulations, PBMs and insurers are accelerating the shift to value-based drug coverage, demanding stronger proof of therapeutic and economic benefit from pharma.